U.S. Markets close in 4 hrs 37 mins

Cyclacel Pharmaceuticals, Inc. (CYCC)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.89+0.02 (+0.41%)
At close: 4:00PM EDT
People also watch
SNSSCYTXAEZSGNVCOPXA

Cyclacel Pharmaceuticals, Inc.

200 Connell Drive
Suite 1500
Berkeley Heights, NJ 07922
United States
908-517-7330
http://www.cyclacel.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees16

Key Executives

NameTitlePayExercisedAge
Mr. Spiro George RombotisChief Exec. Officer, Pres and Exec. Director745.02kN/A57
Mr. Paul McBarronChief Financial Officer, Chief Operating Officer, Exec. VP of Fin., Sec. and Exec. Director453.28kN/A55
Dr. Judy H. Chiao M.D.VP Clinical Devel. and Regulatory Affairs464.16kN/A56
Prof. David Glover Ph.D., FRS FRSEChief ScientistN/AN/A68
Dr. Susan Davis Ph.D.Director of Bus. Devel.N/AN/AN/A
Amounts are as of December 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases. The company’s oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; in Phase II clinical trial for myelodysplastic syndromes; and in Phase I/II clinical trial in combination with seliciclib, a drug candidate to treat solid tumors. Its oncology development programs also comprise Seliciclib, an oral inhibitor of cyclin dependent kinase (CDK) 2/9 enzymes, which are central to the process of cell division and cell cycle control that has completed a Phase IIb clinical trial; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial targeting CDK2/9 enzymes with potential utility in hematological malignancies and solid tumors. In addition, the company’s oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage; and Aurora Kinase inhibitors, a serine/threonine protein kinases that focuses on cell division or mitosis for the treatment of cancer. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Corporate Governance

Cyclacel Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.